Summary Allelic imbalance or loss of heterozygosity (LOH) has been widely used to assess genetic instability in tumours, and high LOH on chromosome arms 3p, 9p and 17p has been considered to be a common event in non-small-cell lung cancer (NSCLC). We have investigated allelic imbalance in 45 NSCLCs using 92 microsatellite markers on 38 chromosome arms. LOH of 38% was observed on 3p using nine markers, 58% on 9p using 15 markers and 38% on 17p using five markers. Fractional allele loss (FAL) Keywords: non-small-cell lung cancer; loss of heterozygosity; fractional allele loss; distinct genetic population Allelic imbalance or loss of heterozygosity (LOH) has been widely used to assess genetic instability in tumour tissues. The technique has been used primarily to identify regions on specific chromosomes that could contain putative tumoursuppressor genes, but may also be used to produce a measure of accumulated genetic damage within the genome of each tumour. A number of such allelotype analyses have been undertaken in lung and in head and neck cancers (Tsuchiya et al., 1992; Sato et al., 1994; Ah-See et al., 1994; Nawroz et al.,1994; Field et al., 1995), the largest of which has been on squamous cell carcinoma of the head and neck (SCCHN) and involved the use of 145 microsatellite markers (Field et al., 1995). In this study fractional allele loss (FAL) was calculated for all tumours for which data on nine or more chromosomal arms were available, and the median value was found to be 0.22 (FAL was al., 1989). A large allelotype of non-smallcell lung cancers (NSCLCs) using 92 markers has also been undertaken by this group and has found a median FAL value of 0.09 (Neville et al., 1996) . Long-term follow-up for this group of NSCLC patients is as yet unavailable, thus no statistical association has been sought between FAL and survival.
Allelic imbalance or loss of heterozygosity (LOH) has been widely used to assess genetic instability in tumour tissues. The technique has been used primarily to identify regions on specific chromosomes that could contain putative tumoursuppressor genes, but may also be used to produce a measure of accumulated genetic damage within the genome of each tumour. A number of such allelotype analyses have been undertaken in lung and in head and neck cancers (Tsuchiya et al., 1992; Sato et al., 1994; Ah-See et al., 1994; Nawroz et al.,1994; Field et al., 1995) , the largest of which has been on squamous cell carcinoma of the head and neck (SCCHN) and involved the use of 145 microsatellite markers (Field et al., 1995) . In this study fractional allele loss (FAL) was calculated for all tumours for which data on nine or more chromosomal arms were available, and the median value was found to be 0.22 (FAL was calculated as the number of chromosome arms showing loss of heterozygosity/number of informative chromosome arms). A correlation between a FAL value above the median and positive lymph nodes at pathology was demonstrated in this study, and also between FAL>median and poor survival. These results are in agreement with an earlier investigation on colonic carcinomas in which a relationship was also shown between FAL > median value and poor survival (Vogelstein et al., 1989) . A large allelotype of non-smallcell lung cancers (NSCLCs) using 92 markers has also been undertaken by this group and has found a median FAL value of 0.09 (Neville et al., 1996) . Long-term follow-up for this group of NSCLC patients is as yet unavailable, thus no statistical association has been sought between FAL and survival.
The presence and role of allelic imbalance on the short arms of chromosomes 3, 9 and 17 in NSCLC has received a Correspondence: JK Field Received 6 March 1996; revised 21 May 1996; accepted 12 July 1996 great deal of attention and it has been argued that these events are associated with the early stages of pathogenesis of these tumours (Sundaresan et al., 1992; Hung et al., 1995; Gazdar et al., 1994; Kishimoto et al., 1995a,b; Thiberville et al., 1995) . In these studies, the investigators studied a small number of dysplastic and neoplastic tissues from the same patient in great detail by performing microdissection of the specimens. All of the six paired dysplastic and tumour tissue specimens investigated by Sundaresan et al. (1992) showed allelic imbalance on 3p and, similarly, Hung et al. (1995) found that six of the seven patients examined with paired preneoplastic and neoplastic lesions showed loss on 3p. Kishimoto et al. (1995b) Neville et al. (1995a) (Table I) . After resection, the tumours were taken fresh from the theatre, snap frozen in liquid nitrogen and each subjected to frozen section histological examination. (Neville et al., 1996) . As these patients have been followed up for less than 18 months, no survival calculations were undertaken.
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In Tables III and IV it may be seen that there was no significant difference in the number of markers used in the analysis of LFAL and HFAL tumour specimens, LFAL (median 80, range 91-69) and HFAL (median 87, range 92-76), thus there was no bias in the analysis of the LFAL and HFAL subgroups.
These 45 NSCLCs were also assessed for microsatellite instability (Field et al., unpublished results), but no association was observed between microsatellite instability and FAL value or LOH on the individual chromosome arms 3p, 9p or 17p. It is of note that one of the four LFAL tumours that had no demonstrable LOH on any chromosomal arm gave evidence of microsatellite instability (L010), and patient L027 was found to have a p53 mutation (Liloglou et al. submitted).
Discussion
Allelic imbalance has been demonstrated in these NSCLC on 3p, 9p and 17p, in agreement with other studies, and correlates with tumours showing a high FAL value: 80% on 3p, 80% on 9p and 73% on 17p, when the FAL values range from 0.14-0.45. However, in tumours with very low FAL values, LOH on these three chromosome arms was found at a low frequency, which is not an unexpected result, since LFAL = 0.0-0.04 and the probability of observing LOH on any one arm increases with increasing FAL values. Previous studies in a small number of NSCLC specimens have shown an association between LOH on 3p and 9p in preneoplastic and neoplastic NSCLC specimens, and the authors argued that this represented one of the earliest genetic events in this disease (Sundaresan et al., 1992; Hung et al., 1995; Kishimoto et al., 1995b; Thiberville et al., 1995) . However our results indicate that these genetic aberrations are only observed in NSCLC tumours that also demonstrate high levels of LOH across the rest of the genome.
The most informative tumours in our analysis are those tumours with the minimum amount of genetic instability (i.e. those with a low FAL value or those with no detectable LOH on any chromosome arm). It can be argued that not all NSCLCs arise from histologically recognisable dysplastic lesions and thus some tumours may never go through this pathologically identifiable route. In the NSCLCs investigated in this study, 9 of the 14 LFAL specimens did not have allelic imbalance at 3p, 9p or 17p, indicating that another geneticinitiating event must be important in these tumours. All of the markers listed in Table III may be considered to represent new target sites in NSCLC; however, only D5S107, D8S261 and D13S175 had greater than 20% LOH in the alleotype study (Neville et al., 1996) .
In the group of four tumours with no LOH identified in this analysis (L004, LOIO, L027 and L036), one tumour (LOIO) was found to have microsatellite instability at D4S194 and patient L027 was found to have a p53 mutation. In addition, no correlation was found between FAL and microsatellite instability (Field et al., unpublished results) , ras mutations in codon 12 (Neville et al., 1995b) 
